Completion of isoniazid–rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness–implementation randomized trial

Fred C Semitala; Jillian L Kadota; Allan Musinguzi; Juliet Nabunje; Fred Welishe; Anne Nakitende; Lydia Akello; Opira Bishop; Devika Patel; Amanda Sammann; Payam Nahid; Robert Belknap; Moses R Kamya; Margaret A Handley; Patrick P J Phillips; Anne Katahoire; Christopher A Berger; Noah Kiwanuka; Achilles Katamba; David W Dowdy; Adithya Cattamanchi

doi:10.1371/journal.pmed.1003875

. 2021 Dec 16;18(12):e1003875. doi: 10.1371/journal.pmed.1003875

Completion of isoniazid–rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness–implementation randomized trial

Fred C Semitala ^1,^2,^3,^‡, Jillian L Kadota ^4,^‡, Allan Musinguzi ², Juliet Nabunje ², Fred Welishe ², Anne Nakitende ², Lydia Akello ², Opira Bishop ², Devika Patel ⁵, Amanda Sammann ⁵, Payam Nahid ⁴, Robert Belknap ⁶, Moses R Kamya ^1,², Margaret A Handley ^7,⁸, Patrick P J Phillips ⁴, Anne Katahoire ⁹, Christopher A Berger ⁴, Noah Kiwanuka ¹⁰, Achilles Katamba ^10,¹¹, David W Dowdy ^11,^12,^‡, Adithya Cattamanchi ^4,^11,^‡,^*

Editor: Claudia M Denkinger¹³

¹Makerere University, Department of Medicine, College of Health Sciences, Kampala, Uganda

²Infectious Diseases Research Collaboration, Kampala, Uganda

³Makerere University Joint AIDS Program, Kampala, Uganda

⁴UCSF Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America

⁵The Better Lab, Department of Surgery, University of California, San Francisco, San Francisco, California, United States of America

⁶Denver Health and Hospital Authority and Division of Infectious Diseases, Department of Medicine, University of Colorado, Denver, Colorado, United States of America

⁷Center for Vulnerable Populations at Zuckerberg San Francisco General Hospital and Trauma Center, University of California, San Francisco, San Francisco, California, United States of America

⁸Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, United States of America

⁹Child Health and Development Center, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda

¹⁰Clinical Epidemiology & Biostatistics Unit, Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda

¹¹Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda

¹²Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America

¹³UniversitatsKlinikum Heidelberg, GERMANY

I have read the journal’s policy and the authors of this manuscript have the following competing interests: AS receives research funding from Global Health Labs, California Health Care Foundation and is owner of The Empathy Studio, LLC. DP is a human-centered design consultant for The Empathy Studio, LLC. The other authors have declared that no competing interests exist.

‡ These authors contributed equally as first authors to this work. AC and DD also contributed equally as senior authors to this work.

^✉

* E-mail: adithya.cattamanchi@ucsf.edu

Roles

Fred C Semitala: Conceptualization, Investigation, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing

Jillian L Kadota: Data curation, Formal analysis, Methodology, Project administration, Visualization, Writing – original draft, Writing – review & editing

Allan Musinguzi: Data curation, Project administration, Supervision, Writing – review & editing

Juliet Nabunje: Data curation, Writing – review & editing

Fred Welishe: Data curation, Writing – review & editing

Anne Nakitende: Data curation, Writing – review & editing

Lydia Akello: Data curation, Writing – review & editing

Opira Bishop: Data curation, Writing – review & editing

Devika Patel: Methodology, Writing – review & editing

Amanda Sammann: Investigation, Methodology, Writing – review & editing

Payam Nahid: Investigation, Writing – review & editing

Robert Belknap: Investigation, Writing – review & editing

Moses R Kamya: Investigation, Writing – review & editing

Margaret A Handley: Investigation, Writing – review & editing

Patrick P J Phillips: Formal analysis, Investigation, Methodology, Writing – review & editing

Anne Katahoire: Investigation, Methodology, Writing – review & editing

Christopher A Berger: Investigation, Methodology, Writing – review & editing

Noah Kiwanuka: Conceptualization, Formal analysis, Investigation, Methodology, Writing – review & editing

Achilles Katamba: Conceptualization, Investigation, Supervision, Writing – review & editing

David W Dowdy: Conceptualization, Investigation, Methodology, Supervision, Writing – review & editing

Adithya Cattamanchi: Conceptualization, Funding acquisition, Investigation, Methodology, Supervision, Writing – review & editing

Claudia M Denkinger: Academic Editor

PMCID: PMC8726462 PMID: 34914696

Abstract

Background

Scaling up shorter regimens for tuberculosis (TB) prevention such as once weekly isoniazid–rifapentine (3HP) taken for 3 months is a key priority for achieving targets set forth in the World Health Organization’s (WHO) END TB Strategy. However, there are few data on 3HP patient acceptance and completion in the context of routine HIV care in sub-Saharan Africa.

Methods and findings

The 3HP Options Trial is a pragmatic, parallel type 3 effectiveness–implementation randomized trial comparing 3 optimized strategies for delivering 3HP—facilitated directly observed therapy (DOT), facilitated self-administered therapy (SAT), or informed choice between DOT and SAT using a shared decision-making aid—to people receiving care at a large urban HIV clinic in Kampala, Uganda. Participants and healthcare providers were not blinded to arm assignment due to the nature of the 3HP delivery strategies. We conducted an interim analysis of participants who were enrolled and exited the 3HP treatment period between July 13, 2020 and April 30, 2021. The primary outcome, which was aggregated across trial arms for this interim analysis, was the proportion who accepted and completed 3HP (≥11 of 12 doses within 16 weeks of randomization). We used Bayesian inference analysis to estimate the posterior probability that this proportion would exceed 80% under at least 1 of the 3HP delivery strategies, a coprimary hypothesis of the trial. Through April 2021, 684 participants have been enrolled, and 479 (70%) have exited the treatment period. Of these 479 participants, 309 (65%) were women, mean age was 41.9 years (standard deviation (SD): 9.2), and mean time on antiretroviral therapy (ART) was 7.8 years (SD: 4.3). In total, 445 of them (92.9%, 95% confidence interval (CI): [90.2 to 94.9]) accepted and completed 3HP treatment. There were no differences in treatment acceptance and completion by sex, age, or time on ART. Treatment was discontinued due to a documented adverse event (AE) in 8 (1.7%) patients. The probability that treatment acceptance and completion exceeds 80% under at least 1 of the three 3HP delivery strategies was greater than 99%. The main limitations are that the trial was conducted at a single site, and the interim analysis focused on aggregate outcome data to maintain blinding of investigators to arm-specific outcomes.

Conclusions

3HP was widely accepted by people living with HIV (PLHIV) in Uganda, and very high levels of treatment completion were achieved in a programmatic setting. These findings show that 3HP can enable effective scale-up of tuberculosis preventive therapy (TPT) in high-burden countries, particularly when delivery strategies are tailored to target known barriers to treatment completion.

Trial registration

ClinicalTrials.gov NCT03934931.

In this interim analysis, Adithya Cattamanchi and colleagues report their findings on 3HP patient acceptance and completion in a routine HIV care context.

Author summary

Why was this study done?

Short course (12 weeks) isoniazid–rifapentine (3HP) is safe and effective for preventing tuberculosis (TB) among people living with HIV (PLHIV) and was recently recommended by the World Health Organization (WHO).
However, data on successful implementation (i.e., high acceptance and completion) in high-burden settings are very limited.
Evidence of successful implementation is critical for informing country-level decisions to scale up 3HP.

What did the researchers do and find?

We conducted an interim analysis of 479 participants in an ongoing randomized trial of 3 strategies for 3HP delivery taking place at a large, urban HIV/AIDS clinic in Kampala, Uganda.
All aspects of 3HP treatment—including counseling, drug administration, side effect monitoring, and adherence evaluation—were done by routine healthcare providers.
Acceptance and completion of 3HP was high (93%, with >99% probability of exceeding 80% in at least 1 trial arm). Only 8 (1.7%) patients discontinued 3HP treatment due to an adverse event (AE).

What do these findings mean?

High levels of 3HP acceptance and completion can be achieved in the context of routine HIV/AIDS care in sub-Saharan Africa.
HIV/AIDS programs in sub-Saharan Africa should consider scaling up 3HP as an alternative to isoniazid preventive therapy.
Further research is needed to confirm that the facilitation strategies evaluated in the 3HP Options Trial are feasible in other settings and needed to enhance treatment acceptance and completion.

Introduction

Tuberculosis (TB) is curable and preventable, yet remains a leading cause of death among people living with HIV (PLHIV) [1]. Tuberculosis preventive therapy (TPT) can reduce TB incidence and mortality by 30% to 50% [2,3] and is recommended for all PLHIV in high TB burden settings. Access to TPT has improved recently, with 3.5 million PLHIV receiving TPT in 2019 [1]. However, in many settings, less than half of those initiating TPT with the standard 6-month course of daily isoniazid complete treatment [4–6].

Safer, shorter TPT regimens are now available, including a 12-dose weekly regimen of isoniazid–rifapentine (3HP) [7–9]. In 2018, the World Health Organization (WHO) recommended 3HP as an option for TPT, citing its shortened duration as an enabler of treatment adherence and completion [1]. The Phase IV multicenter iAdhere trial conducted primarily in the United States found that 3HP treatment completion was 87.2% with directly observed therapy (DOT), 74% with self-administered therapy (SAT), and 76.4% with SAT plus short messaging service (SMS) reminders [10]. However, data on acceptance and completion of 3HP from high-burden settings—particularly in sub-Saharan Africa—remain sparse, posing a major barrier to widespread uptake and implementation [11,12]. Notably, in the iAdhere trial, noninferiority of SAT to DOT was only demonstrated among participating sites in the US, with SAT performing worst (37% treatment completion) in South Africa, the only participating African site. These findings further underscore the need for evidence of 3HP acceptability and completion in high-burden settings like Uganda. Under the recommendation of our external Trial Steering Committee and taking into account the urgent need for data from high-burden settings to support country-level decisions regarding 3HP scale-up, we undertook an interim analysis of the 3HP Options Trial, a randomized trial of 3 facilitated strategies for delivering 3HP to PLHIV receiving routine HIV/AIDS care in Uganda.

Methods

Study design and participants

The 3HP Options Trial is an ongoing 3-arm, parallel, individual participant randomized trial with a hybrid type 3 effectiveness–implementation design. Hybrid effectiveness–implementation trials assess both effectiveness and implementation outcomes, with type I designs having a greater focus on intervention effectiveness and type 3 designs having a greater focus on implementation strategies and outcomes [13]. Our overall goal as a type 3 hybrid design is to identify the optimal implementation strategy (facilitated DOT, facilitated SAT, or patient choice) for enabling completion of 3HP (i.e., the evidence-based intervention), while also adding to the large body of evidence demonstrating its safety and effectiveness. The trial is being conducted among adults accessing HIV/AIDS care at the Mulago Immune Suppression Syndrome (ISS; i.e., HIV/AIDS) clinic in Kampala, Uganda. This clinic is the largest outpatient HIV clinic in Uganda (over 16,000 PLHIV enrolled and 300 new PLHIV registered monthly), and scale-up of TPT is a key priority for clinic leadership as well as the Uganda National Tuberculosis and Leprosy Programme and AIDS Control Programme at the Uganda Ministry of Health.

Details of the trial design—including full eligibility criteria—have been published previously [14]. Briefly, the trial included adults (age ≥18 years) living with HIV engaged in care at the Mulago ISS clinic. PLHIV were excluded if they were ineligible for 3HP treatment (e.g., a baseline alanine aminotransferase [ALT] level or aspartate transaminase [AST] level >3 times the upper limit of normal) or had a logistical issue that impeded participation in the trial (e.g., unable to provide consent) (Fig 1).

Fig 1 — *3HP Options Trial screening*, randomization, and allocation, July 13, 2020 to April 30, 2021 (n = 1,133). ALT, alanine aminotransferase; AST, aspartate transaminase; CONSORT, Consolidated Standards of Reporting Trials; INH, isoniazid; RPT, rifapentine; TB, tuberculosis.

Trial enrollment began in July 2020 and is anticipated to be completed in October 2022. The trial was approved by institutional review boards at Makerere University School of Public Health Higher Degrees, Research and Ethics Committee, the University of California, San Francisco Human Research Protection Program, and by the Uganda National Council for Science and Technology. The trial is registered on ClinicalTrials.gov (NCT03934931). Plans to report an interim analysis were reviewed and approved by the independent Trial Steering Committee.

Randomization and interventions

Briefly, eligible participants who provide written informed consent are randomized to 1 of 3 optimized delivery strategies for receiving 3HP. The delivery strategies were designed to address barriers to 3HP acceptance and completion identified in formative research [15–17] and with involvement of local stakeholders including PLHIV, clinicians, and clinic/program leadership to maximize acceptability and feasibility.

The trial protocol paper provides full details of the components of the 3 delivery strategies: facilitated DOT, facilitated SAT, and patient choice between facilitated DOT and facilitated SAT (with the assistance of a decision aid) [14]. Briefly, all strategies included (a) standardized patient counseling about the risks and benefits of 3HP; (b) streamlined clinic visits (11 visits for DOT and 2 for SAT) at the pharmacy window for symptom-based TB screening and side effects screening using a standardized checklist (S1 Text); (c) reimbursement of transport costs for clinic visits; and (d) automated interactive voice response (IVR) reminders for clinic visits. The transport reimbursement was provided by pharmacy technicians with the amount standardized based on an assessment of average local transportation costs and stakeholder assessment of programmatic feasibility at scale. For participants randomized to the facilitated DOT arm, all 3HP doses were provided at weekly clinic visits. For participants randomized to the facilitated SAT arm, the first, sixth, and final 3HP doses were directly observed at clinic visits. The remaining doses were self-administered, and participants were asked to report dosing completion using the 99DOTS platform (Everwell Health Solutions, India). 99DOTS is a low-cost digital adherence technology wherein patients call random toll-free numbers prepackaged with each medication dose, and the calls are logged on the 99DOTS server to generate a real-time dosing history that health workers can monitor [18]. The 99DOTS platform was also used to send automated weekly IVR check-in calls asking “Are you well?” to assess for potential adverse events (AEs). For participants randomized to the choice arm, a decision aid was used to offer an informed choice between the facilitated DOT and facilitated SAT strategies. The decision aid was codesigned with PLHIV to help patients prioritize their values and choose the option that best aligned with their preferences. Participants in the choice arm could switch delivery strategies at any time.

Assessments and data collection

Research staff screened PLHIV for eligibility, obtained informed consent from eligible participants, administered a baseline demographic and clinical survey, and performed randomization. Participants were then transferred to routine healthcare providers who performed all activities related to 3HP counseling, AE monitoring, dosing and adherence monitoring, and follow-up [14]. Healthcare providers did not receive any incentives or payments for delivering care related to 3HP. For AE monitoring, pharmacy technicians were asked to screen participants for potential side effects using a standardized checklist at clinic visits prior to 3HP dosing or by calling SAT participants who responded “No” to the weekly IVR check-in and to refer participants with potential side effects to a routine clinician for further evaluation. Further assessment including any laboratory testing was at the discretion of the clinician. Completion was assessed using the 99DOTS platform (i.e., weekly confirmation of self-administered doses by patient phone calls, with clinic-administered doses logged by pharmacy technicians on patients’ behalf). Self-administered doses were further verified by pharmacy technician pill count. Pharmacy technicians were asked to review participant dosing histories and call participants who missed clinic visits or did not call the 99DOTS platform to report expected self-administered doses.

To extract AE-related data, research staff retrospectively reviewed (on a weekly basis) the AEs checklist completed by pharmacy technicians and clinic charts of all participants referred to a clinician for further evaluation of a potential AE. Research staff noted whether the clinician documented the potential AE to be 3HP related and whether 3HP treatment was continued, held, or discontinued permanently. To assess 3HP initiation and completion among participants in all 3 trial arms, research staff extracted weekly 3HP dosing data from the 99DOTS server.

Trial outcomes

Trial outcomes were developed using the RE-AIM evaluation framework [19]. The primary outcome is the proportion of randomized participants who accept 3HP treatment and complete at least 11 of the 12 weekly doses within 16 weeks of enrollment [7,9,10], which reflects intervention reach (acceptance) and fidelity (treatment completion). In addition, this interim analysis assessed the proportion of participants initiating 3HP treatment who had a serious AE, defined as any AE resulting in treatment discontinuation, which reflects the effectiveness domain of the RE-AIM framework. Additional trial effectiveness and implementation outcomes are described in the published trial protocol [14] and will be reported upon completion of the trial.

Statistical analysis

Our interim analysis included simple calculation (using exact binomial 95% confidence intervals (CIs)) of outcomes aggregated across trial arms overall and stratified by sex, age, and time on ART. We used Bayesian inference to estimate the posterior probability that the proportion of PLHIV who accept and complete 3HP would exceed 0.8 under at least 1 of the 3 delivery strategies being compared (a coprimary trial hypothesis, as prespecified in the trial protocol). We used a beta distribution for the primary outcome and used a noninformative flat conjugate beta (1,1) prior. We conservatively assumed that outcomes were distributed equally across the 3 study arms; if outcomes were distributed unequally, the probability of the outcome proportion exceeding 0.8 would be higher in at least 1 arm. We then calculated the posterior probability that the proportion accepting and completing 3HP in a single arm exceeded 0.8 using standard methods taking advantage of the conjugate beta prior [20].

Results

From July 2020 through April 2021, 1,133 PLHIV accessing care at Mulago ISS clinic were screened for participation, and 226 (20%) had a contraindication to 3HP. Of the remaining 907 PLHIV who were in the target population for 3HP-based TPT, 223 (25%) were excluded for trial-specific reasons. Thus, 684 participants were randomized, and 479 participants who had exited the 16-week treatment period were included in the interim analysis (Fig 1). Of these 479 participants, 309 (65%) were women, mean age was 41.9 years (standard deviation (SD): 9.2), and mean time on antiretroviral therapy (ART) was 7.8 years (SD: 4.3; Table 1).

Table 1. Baseline demographic and clinical characteristics.

3HP Options Trial participants, July 13, 2020 to April 30, 2021 (n = 479).

Total randomized	N = 479
Clinical	Mean (SD), n (%)
Age	41.9 (9.2)
Female sex	309 (64.5%)
Prior TB	90 (18.8%)
On ART	479 (100.0%)
Years on ART	7.8 (4.3)
Most recent CD4 count	1,223 (2,344)
BMI (4 participants missing BMI)	26.1 (5.4)
Typical travel time to clinic (hours)	1.1 (0.7)
Sociodemographic
Employment status
Student	5 (1.0)
Not employed	57 (11.9)
Self-employed	245 (51.2)
Hired worker	47 (9.8)
Temporary/informal work	125 (26.1)
Education level
None	41 (8.6)
Primary	222 (46.4)
Secondary	175 (36.5)
Vocational training/tertiary	24 (5.0)
Postsecondary	17 (3.6)
MPI category ¹
Not vulnerable to poverty	180 (37.6)
Not poor but vulnerable to poverty	182 (38.0)
Multidimensionally poor	90 (18.8)
Severely multidimensionally poor	27 (5.6)

Open in a new tab

¹. The global MPI examines deprivations across 10 indicators in dimensions of health, education, and standards of living, with those deprived in one-third or more of the 10 indicators counted as being multidimensionally poor [21].

Health and education indicators are weighted at 1/6 each and standard of living indicators are weighted 1/18 each. MPI values can range from 0 to 1, with greater values indicating higher poverty. Variables included in our calculation of MPI category included (1) child mortality in the last 5 years; (2) years of schooling among household members 10 years and above; (3) school attendance among school-age children; (4) type of cooking fuel; (5) toilet type; (6) type/source of main drinking water; (7) availability of electricity; (8) type of floor material; and (9) ownership of a mobile phone, computer, or car/truck.

ART, antiretroviral therapy; BMI, body mass index; SD, standard deviation; TB, tuberculosis.

Primary outcome

In total, 445 (92.9%, 95% CI: 90.2 to 94.9) participants accepted 3HP and completed at least 11 of 12 doses within 16 weeks (Fig 2). The mean length of follow-up among those completing treatment was 78.4 days (SD: 3.5 days) and ranged from 72 days to 109 days. The longest treatment interruption among any participant reaching the primary outcome was 28 days. Treatment acceptance and completion was similarly high among men and women, younger (18 to 41 years) and older (≥42 years) participants, and participants on ART for shorter (≤1 year) and longer (>1 year) durations (Fig 2). The posterior probability that treatment acceptance and completion would exceed 0.8 under at least 1 of the 3 delivery strategies was estimated to be 99.9%.

Secondary outcomes

A total of 34 (7.1%) participants did not complete 3HP treatment. Treatment was permanently discontinued due to a suspected 3HP-related AE in 8 (1.7%) participants (4 with pruritic rash, 1 with venous thromboembolism in the right leg, 1 with flu-like syndrome and peripheral neuropathy, 1 with pulmonary embolism, and 1 with acute liver injury—see S2 Text for additional details). In addition, 2 (0.4%) participants did not initiate treatment, 21 (4.4%) were lost to follow-up (did not take at least 11 doses of 3HP within 16 weeks), 1 (0.2%) had treatment discontinued after becoming pregnant, 1 (0.2%) had treatment discontinued due to starting new medications with known 3HP drug interaction (clarithromycin, omeprazole, and domperidone), and 1 (0.2%) died in a motor vehicle accident.

Discussion

In this interim analysis of an ongoing randomized trial among PLHIV in Uganda, we found extremely high acceptance and completion of 3HP with facilitated delivery strategies that all included dosing reminders, streamlined clinic visits, and reimbursement of transport costs. This treatment was also well tolerated, with less than 2% of PLHIV discontinuing treatment due to a documented AE. Taken together, these results demonstrate high levels of 3HP uptake and completion can be achieved in the context of routine HIV/AIDS care with delivery strategies designed to address known barriers to 3HP completion.

Mounting evidence of the benefits of shorter and safer rifapentine-containing regimens [7,22,23] has led to recommendations by WHO and others to implement 3HP for global scale-up of TPT. In low-burden and/or high-income countries, 3HP completion has been reported to be similar or higher in routine healthcare settings than rates reported in controlled clinical trials [24–27]. The initial Phase IV trial of 3HP, however, demonstrated poor treatment completion in its only participating African site, particularly when self-administered (38% to 50%) [10]. Recently, Churchyard and colleagues reported that treatment completion was 90.4% for self-administered 3HP versus 50.5% for 6 months of self-administered daily isoniazid in a randomized trial among PLHIV in South Africa, Ethiopia and Mozambique [28]. This trial extends those latter findings, demonstrating that similar (if not higher) levels of treatment completion can be achieved with routine healthcare providers overseeing 3HP counseling, AEs monitoring, dosing, and adherence monitoring. These data support the recent change in the Uganda HIV prevention and treatment guidelines to recommend 3HP as an alternative to isoniazid preventive therapy [29] and may encourage similar policy decisions in other high HIV/TB burden settings.

Importantly, the results reported here were achieved with the use of facilitated delivery strategies. The strategies were designed using an implementation science-based approach to target key barriers to 3HP acceptance and completion, and local stakeholders were involved in the design process to maximize acceptability and scale up potential [14–17]. The final analysis of results from the full trial is needed to determine whether one of the strategies is more or less effective than the others. However, results from this interim analysis suggest that, when scaling up 3HP, programs should consider facilitation strategies that meet the needs and preferences of PLHIV and HIV care providers in sub-Saharan Africa [30].

This interim analysis also demonstrates how data from an ongoing randomized trial can be used to inform a time-sensitive public health question while maintaining blinding of investigators to differences between arms. Further discussion is warranted among the scientific community as to when and how interim analyses of randomized trials—particularly trials focused on improving implementation of proven interventions—should be performed to inform public health decisions.

Our analysis has some limitations. First, we only assessed outcomes aggregated across trial arms. Arm-specific details have not been provided to maintain the integrity of the ongoing trial; full trial results including comparison by arm will be presented at trial completion. Nevertheless, even when conservatively assuming that completion rates are similar across arms, our Bayesian analysis suggests a greater than 99% probability of exceeding 80% initiation and completion under at least 1 delivery strategy. Second, the trial was conducted at a single HIV/AIDS clinic in Uganda. However, the setting is similar to the US President’s Emergency Plan for AIDS Relief (PEPFAR)-funded HIV/AIDS clinics in other countries in sub-Saharan Africa, where similar barriers to completion of TPT have been widely reported [31–38]. Third, some of the facilitation strategies evaluated as part of the 3HP Options Trial are not likely to be part of usual care at most HIV/AIDS clinics in sub-Saharan Africa and would require additional funding to implement as part of 3HP scale-up. However, with increasing access to smartphones and internet in resource-limited settings, there is need for creative and inexpensive innovations to leverage this technological development to enhance health service delivery.

In conclusion, we observed extremely high acceptance and completion of 3HP for prevention of TB when delivered in a facilitated manner (i.e., with dosing reminders, streamlined visits, and reimbursement of transport costs) among PLHIV in Uganda. These interim results lend evidence to donors, policymakers, and program officials supporting the scale-up of 3HP in Uganda and elsewhere and provide some of the first data describing high 3HP completion in a high-burden setting. The findings also highlight the importance of delivering 3HP using a patient-centered approach to optimize treatment completion and thus impact on reducing the burden of TB disease and mortality among PLHIV.

Supporting information

S1 CONSORT Checklist. CONSORT 2010 checklist of information to include when reporting a randomized trial.

CONSORT, Consolidated Standards of Reporting Trials.

(DOC)

Click here for additional data file.^{(94.5KB, doc)}

S1 StaRI Checklist. StaRI: The StaRI checklist for completion.

StaRI, Standards for Reporting Implementation Studies.

(DOCX)

Click here for additional data file.^{(43.6KB, docx)}

S1 Data. Raw deidentified data used to conduct this analysis.

Each row corresponds to a trial participant. The dataset includes 14 columns: Enrollment date; Age; Sex; BMI; On ART; Years on ART; Prior TB; One-way travel time to clinic (hours); Education level (none, primary, secondary, postsecondary (university or graduate school), or vocational/tertiary); Employment status (not employed, self-employed, temporary/informal work, hired worker, or student); MPI category (severely multidimensionally poor, multidimensionally poor but not severely, not poor but vulnerable to becoming poor, or not poor nor vulnerable to becoming poor); Outcome date; Outcome reason (completed 3HP treatment, missed 6 or more doses, stopped 3HP due to a documented AE, never initiated 3HP treatment, pregnancy, new medication with 3HP drug–drug interaction, other reason, or specify (died in a motor vehicle accident); Primary outcome (≥11 of 12 doses within 16 weeks of randomization). AE, adverse event; ART, antiretroviral therapy; BMI, body mass index; MPI, Multidimensional Poverty Index; TB, tuberculosis.

(CSV)

Click here for additional data file.^{(65.4KB, csv)}

S1 Statistical Analysis Plan. 3HP Options Trial: Interim analysis statistical analysis plan.

(DOCX)

Click here for additional data file.^{(96.3KB, docx)}

S1 Trial Protocol. Options for delivering isoniazid–rifapentine (3HP) for TB prevention (3HP options implementation trial).

TB, tuberculosis.

(DOCX)

Click here for additional data file.^{(263.7KB, docx)}

S1 Text. Side effects and symptom-based TB screening checklist.

TB, tuberculosis.

(DOCX)

Click here for additional data file.^{(16KB, docx)}

S2 Text. Serious AEs summary.

AE, adverse event.

(DOCX)

Click here for additional data file.^{(22KB, docx)}

Acknowledgments

The authors are grateful to the administration, staff, and patients at the Makerere University Joint AIDS Program Mulago ISS clinic for their time and participation. We also thank the Infectious Diseases Research Collaboration, the Uganda TB Implementation Research Consortium (U-TIRC), and the Uganda National Tuberculosis and Leprosy Programme for supporting the study.

Abbreviations

AE: adverse event
ALT: alanine aminotransferase
ART: antiretroviral therapy
AST: aspartate transaminase
CI: confidence interval
DAT: digital adherence technology
DOT: directly observed therapy
ISS: Immune Suppression Syndrome
IVR: interactive voice response
MPI: Multidimensional Poverty Index
PEPFAR: President’s Emergency Plan for AIDS Relief
PLHIV: people living with HIV
SAT: self-administered therapy
SD: standard deviation
SMS: short messaging service
TB: tuberculosis
TPT: tuberculosis preventive therapy
ULN: upper limit of normal
WHO: World Health Organization

Data Availability

All relevant data are within the manuscript and its Supporting information files.

Funding Statement

This study is supported by a grant from the US National Heart, Lung and Blood Institute: NIH/NHLBI R01HL144406 (AC); https://www.nhlbi.nih.gov/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1.World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization; 2020.
2.Group TAS, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015;373(9):808–22. doi: 10.1056/NEJMoa1507198 [DOI] [PubMed] [Google Scholar]
3.Badje A, Moh R, Gabillard D, Guehi C, Kabran M, Ntakpe JB, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–e9. doi: 10.1016/S2214-109X(17)30372-8 [DOI] [PubMed] [Google Scholar]
4.Melgar M, Nichols C, Cavanaugh JS, Kirking HL, Surie D, Date A, et al. Tuberculosis Preventive Treatment Scale-Up Among Antiretroviral Therapy Patients—16 Countries Supported by the U.S. President’s Emergency Plan for AIDS Relief, 2017–2019. MMWR Morb Mortal Wkly Rep. 2020;69(12):329–34. doi: 10.15585/mmwr.mm6912a3 [DOI] [PMC free article] [PubMed] [Google Scholar]
5.Roscoe C, Lockhart C, de Klerk M, Baughman A, Agolory S, Gawanab M, et al. Evaluation of the uptake of tuberculosis preventative therapy for people living with HIV in Namibia: a multiple methods analysis. BMC Public Health. 2020;20(1):1838. doi: 10.1186/s12889-020-09902-z [DOI] [PMC free article] [PubMed] [Google Scholar]
6.Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269–78. doi: 10.1016/S1473-3099(16)30216-X [DOI] [PubMed] [Google Scholar]
7.Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66. doi: 10.1056/NEJMoa1104875 [DOI] [PubMed] [Google Scholar]
8.Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11–20. doi: 10.1056/NEJMoa1005136 [DOI] [PMC free article] [PubMed] [Google Scholar]
9.Moro RN, Borisov AS, Saukkonen J, Khan A, Sterling TR, Villarino ME, et al. Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada. Clin Infect Dis. 2016;62(11):1390–400. doi: 10.1093/cid/ciw126 [DOI] [PMC free article] [PubMed] [Google Scholar]
10.Belknap R, Holland D, Feng PJ, Millet JP, Cayla JA, Martinson NA, et al. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. Ann Intern Med. 2017;167(10):689–97. doi: 10.7326/M17-1150 [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Yuen CM, Majidulla A, Jaswal M, Safdar N, Malik AA, Khan AJ, et al. Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting. Clin Infect Dis. 2021;73(5):e1135–e41. doi: 10.1093/cid/ciaa1835 [DOI] [PMC free article] [PubMed] [Google Scholar]
12.Cui X, Gao L, Cao B. Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries. Int J Infect Dis. 2020;92S:S37–40. doi: 10.1016/j.ijid.2020.02.034 [DOI] [PubMed] [Google Scholar]
13.Brown CH, Curran G, Palinkas LA, Aarons GA, Wells KB, Jones L, et al. An Overview of Research and Evaluation Designs for Dissemination and Implementation. Annu Rev Public Health. 2017;38:1–22. doi: 10.1146/annurev-publhealth-031816-044215 [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, et al. Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implement Sci. 2020;15(1):65. doi: 10.1186/s13012-020-01025-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Kadota JL, Katamba A, Musinguzi A, Welishe F, Nabunje J, Ssemata JL, et al. Willingness to accept reimbursement for visits to an HIV clinic for tuberculosis preventive therapy. Int J Tuberc Lung Dis. 2020;24(7):729–31. doi: 10.5588/ijtld.20.0010 [DOI] [PMC free article] [PubMed] [Google Scholar]
16.Lim RK, Semitala FC, Atuhumuza E, Sabiti L, Namakula-Katende J, Muyindike WR, et al. Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda. PLoS ONE. 2021;16(2):e0246113. doi: 10.1371/journal.pone.0246113 [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Semitala FC, Musinguzi A, Ssemata JL, Welishe F, Nabunje J, Kadota JL, et al. Acceptance and completion of rifapentine based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda—patient and health worker perspectives. Implementation Science. IDAA Commun. 2021;2. doi: 10.1186/s43058-021-00173-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
18.Subbaraman R, de Mondesert L, Musiimenta A, Pai M, Mayer KH, Thomas BE, et al. Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities. BMJ Glob Health. 2018;3(5):e001018. doi: 10.1136/bmjgh-2018-001018 [DOI] [PMC free article] [PubMed] [Google Scholar]
19.Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322–7. doi: 10.2105/ajph.89.9.1322 [DOI] [PMC free article] [PubMed] [Google Scholar]
20.Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, DB R. Bayesian data analysis. Boca Raton: CRC Press; 2014. [Google Scholar]
21.Global Multidimensional Poverty index 2020 –Charting Pathways out of Multidimensional Poverty: Achieving the SDGs. UNDP and OPHI. 2020.
22.Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JA, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69(4):1079–85. doi: 10.1093/jac/dkt483 [DOI] [PMC free article] [PubMed] [Google Scholar]
23.Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, et al. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. Clin Infect Dis. 2015;61(8):1322–7. doi: 10.1093/cid/civ464 [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Sandul AL, Nwana N, Holcombe JM, Lobato MN, Marks S, Webb R, et al. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection. Clin Infect Dis. 2017;65(7):1085–93. doi: 10.1093/cid/cix505 [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Walker RE, Bass S, Srinivas P, Miranda C, Johnson L, Pallotta AM. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection. Ann Pharmacother. 2020;54(5):457–63. doi: 10.1177/1060028019888855 [DOI] [PubMed] [Google Scholar]
26.Sun HY, Huang YW, Huang WC, Chang LY, Chan PC, Chuang YC, et al. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan. Tuberculosis (Edinb). 2018;111:121–6. doi: 10.1016/j.tube.2018.05.013 [DOI] [PubMed] [Google Scholar]
27.Haas MK, Aiona K, Erlandson KM, Belknap RW. Higher Completion Rates with Self-administered Once-weekly Isoniazid-Rifapentine versus Daily Rifampin in Adults with Latent Tuberculosis. Clin Infect Dis. 2020. [DOI] [PubMed] [Google Scholar]
28.Churchyard G, Cardenas V, Chihota V, Mngadi K, Sebe M, Brumskine W, et al. Annual Tuberculosis Preventive Therapy for Persons With HIV Infection: A Randomized Trial. Ann Intern Med. 2021. doi: 10.7326/M20-7577 [DOI] [PubMed] [Google Scholar]
29.Consolidated Guidelines for the Prevention and Treatment of HIV and AIDS in Uganda. In: Ministry of Health, Kampala, Uganda. 2020.
30.Yuen CM, Millones AK, Galea JT, Puma D, Jimenez J, Lecca L, et al. Toward patient-centered tuberculosis preventive treatment: preferences for regimens and formulations in Lima, Peru. BMC Public Health. 2021;21(1):121. doi: 10.1186/s12889-020-10098-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
31.Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, et al. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS. 2010;24(Suppl 5):S57–65. doi: 10.1097/01.aids.0000391023.03037.1f [DOI] [PubMed] [Google Scholar]
32.Jacobson KB, Niccolai L, Mtungwa N, Moll AP, Shenoi SV. "It’s about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa. AIDS Care. 2017;29(7):936–42. doi: 10.1080/09540121.2017.1283390 [DOI] [PMC free article] [PubMed] [Google Scholar]
33.Rowe KA, Makhubele B, Hargreaves JR, Porter JD, Hausler HP, Pronyk PM. Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings? Int J Tuberc Lung Dis. 2005;9(3):263–9. [PubMed] [Google Scholar]
34.Mindachew M, Deribew A, Memiah P, Biadgilign S. Perceived barriers to the implementation of Isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study. Pan Afr Med J. 2014;17:26. doi: 10.11604/pamj.2014.17.26.2641 [DOI] [PMC free article] [PubMed] [Google Scholar]
35.Kim HY, Hanrahan CF, Dowdy DW, Martinson NA, Golub JE, Bridges JFP. Priorities among HIV-positive individuals for tuberculosis preventive therapies. Int J Tuberc Lung Dis. 2020;24(4):396–402. doi: 10.5588/ijtld.18.0740 [DOI] [PMC free article] [PubMed] [Google Scholar]
36.Cowan J, Greenberg Cowan J, Barnhart S, Demamu S, Fiseha D, Graham W, et al. A qualitative assessment of challenges to tuberculosis management and prevention in Northern Ethiopia. Int J Tuberc Lung Dis. 2013;17(8):1071–5. doi: 10.5588/ijtld.12.0240 [DOI] [PMC free article] [PubMed] [Google Scholar]
37.Gust DA, Mosimaneotsile B, Mathebula U, Chingapane B, Gaul Z, Pals SL, et al. Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana. PLoS ONE. 2011;6(4):e18435. doi: 10.1371/journal.pone.0018435 [DOI] [PMC free article] [PubMed] [Google Scholar]
38.Makanjuola T, Taddese HB, Booth A. Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: a systematic review of qualitative data. PLoS ONE. 2014;9(2):e87166. doi: 10.1371/journal.pone.0087166 [DOI] [PMC free article] [PubMed] [Google Scholar]

PLoS Med. doi: 10.1371/journal.pmed.1003875.r001

Decision Letter 0

Callam Davidson

26 Aug 2021

Dear Dr Cattamanchi,

Thank you for submitting your manuscript entitled "Completion of Isoniazid-Rifapentine (3HP) for tuberculosis (TB) prevention among people living with HIV (PLHIV): interim analysis of the 3HP Options Trial" for consideration by PLOS Medicine.

Your manuscript has now been evaluated by the PLOS Medicine editorial staff and I am writing to let you know that we would like to send your submission out for external peer review.

However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire.

Please re-submit your manuscript within two working days, i.e. by Aug 30 2021 11:59PM.

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. Once your manuscript has passed all checks it will be sent out for review.

Feel free to email us at plosmedicine@plos.org if you have any queries relating to your submission.

Kind regards,

Callam Davidson

Associate Editor

PLOS Medicine

PLoS Med. doi: 10.1371/journal.pmed.1003875.r002

Decision Letter 1

Callam Davidson

7 Oct 2021

Dear Dr. Cattamanchi,

Thank you very much for submitting your manuscript "Completion of Isoniazid-Rifapentine (3HP) for tuberculosis (TB) prevention among people living with HIV (PLHIV): interim analysis of the 3HP Options Trial" (PMEDICINE-D-21-03667R1) for consideration at PLOS Medicine.

Your paper was evaluated by an associate editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

[LINK]

In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers' and editors' comments. You will understand that we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: http://journals.plos.org/plosmedicine/s/figures. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at PLOSMedicine@plos.org.

We hope to receive your revised manuscript by Oct 28 2021 11:59PM. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: http://journals.plos.org/plosmedicine/s/competing-interests.

Please use the following link to submit the revised manuscript:

https://www.editorialmanager.com/pmedicine/

Your article can be found in the "Submissions Needing Revision" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript and please get in touch if you have any questions.

Sincerely,

Callam Davidson,

PLOS Medicine

cdavidson@plos.org

-----------------------------------------------------------

Requests from the editors:

As a general comment, please consider toning down your statement of generalisability to other programmatic settings (considering the single country setting and investment that would be required to make the interventions more widely available).

Please revise your title to indicate that this is an implementation science study. Your title should begin with with main concept if possible. Please place the study design (e.g. "a randomized hybrid type 3 effectiveness-implementation trial”, or similar) design in the subtitle (i.e., after the colon).

Please report your abstract according to CONSORT for abstracts, following the PLOS Medicine abstract structure (Background, Methods and Findings, Conclusions) http://www.consort-statement.org/extensions?ContentWidgetId=562v

Abstract:

• Please combine the Methods and Findings sections into one section, “Methods and findings”.

• Please specify who was blinded to the intervention arms.

• Please indicates the dates during which study enrollment and follow up occurred.

• Please include the main outcome measures.

• In the last sentence of the Abstract Methods and Findings section, please describe the main limitation(s) of the study's methodology.

At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary

Please update the section heading ‘Background’ to ‘Introduction’

Please provide a definition of hybrid trials and your justification for using a hybrid type 3 effectiveness implementation design, as some readers may not be familiar with the term

Please differentiate your clinical and implementation outcomes. It will be helpful to specify implementation outcomes using standard Implementation Science terminology such as e.g., acceptability, sustainability. This tool may be of use https://cpb-us-w2.wpmucdn.com/sites.wustl.edu/dist/6/786/files/2017/08/DIRC-implementation-outcomes-tool-dg_7-27-17_ab-27xbrka.pdf

Please clearly specify and report your implementation strategies. Consider using the guidelines published by Proctor et al. to improve your reporting: Proctor EK, Powell BJ, McMillen JC: Implementation strategies: recommendations for specifying and reporting. Implement Sci 2013, 8:139

Please provide the names of the institutional review boards that provided ethical approval.

Please define the length of follow up (eg, in mean, SD, and range).

Citations should be in square brackets, please update throughout.

Please complete the CONSORT checklist and ensure that all components of CONSORT are present in the manuscript.

When completing the checklist, please use section and paragraph numbers, rather than page numbers.

In addition to the CONSORT checklist please ensure that your implementation research is reported according to Standards for Reporting Implementation Studies statement (STARI). The STARI guidelines can be found here: https://www.equator-network.org/reporting-guidelines/stari-statement/

In accordance with ICMJE requirements, PLOS Medicine requires prospective, public registration of a data sharing plan (as part of mandatory clinical trials registration) for all clinical trials that began enrollment on or after January 1, 2019.

Please include the study protocol document and analysis plan, with any amendments, as Supporting Information to be published with the manuscript if accepted.

Comments from the reviewers:

Reviewer #1: "Completion of Isoniazid-Rifapentine (3HP) for tuberculosis (TB) prevention among people living with HIV (PLHIV): interim analysis of the 3HP Options Trial" describes interim results for a randomized trial involving three arms, each investigating different therapy strategies: facilitated directly observed therapy (DOT), facilitated self-administered therapy (SAT), or informed choice between DOT and SAT. From 479 trial participants (approximately equally divided between the arms) having exited the treatment period, it was found that some 93% had completed the 3HP treatment, under the definition of having at least 11 of 12 doses taken within the 16-week period. This was analyzed as having a greater than 99% probability, that treatment acceptance and completion would exceed 80% under at least one of the three strategies.

The prompt addressing of curable TB is an important issue with clear benefits in mitigating death, especially amongst individuals with HIV. The 3HP randomized trial as described appears a significant contribution towards assessing treatment programmes in an African context. Additionally, the underlying raw data has also been provided as supplementary material. However, some reservations might be addressed:

1. The manuscript as it stands is fairly concise and focused. However, while the importance of the trial should not be understated, it is unclear as to whether an official publication on interim results is strictly warranted, especially as the trial is expected to complete by October 2022 (Line 103). It might be considered to support more strongly the case for publishing interim results (e.g. the trial qualifying for early stopping, in which case the analysis supporting early stopping might be presented; early stopping however does not appear to be catered for in the trial protocol, cited as [10])

2. More details or relevant citations on the Bayesian inference framework used (currently briefly described under the Statistical Analysis section from Line 134) for the main analysis, would be illuminating.

3. While Figure 2 contains primary outcome results stratified by subgroups, there does not appear analysis relating to delivery strategies (although existing results do indeed suggest that the various strategies likely result in treatment completion rates well in excess of 0.80). The Bayesian inference analysis framework might thus be explained in greater detail, and results also presented by treatment strategy (possibly also stratified by the existing subgroups in Figure 2)

4. Related to the above, the demographic characteristics in Table 1 might also be further stratified by treatment strategy, for completeness.

Reviewer #2: This manuscript presents an interim analysis of outcome data aggregated across arms of the 3HP Options trial. While the trial's primary objective is to compare different methods of delivering 3HP, the interim analysis presents treatment completion and adverse event outcomes for patients in all three arms together. A very high proportion of patients accepted and completed treatment. Given that this interim analysis does not address the question of how best 3HP can be delivered in a high-burden setting, its importance is framed as providing one of the first examples of 3HP being delivered in a programmatic setting in a high-burden country. While I agree that publishing such examples is very important, I also think that the way the authors frame this report perhaps oversimplifies the situation; my concerns on this matter are described in comments 1 and 2 below.

Specific comments:

1) The argument that this publication reflects treatment completion achieved in a programmatic setting in a high-burden setting is key to the authors' justification of its importance. However, this is a randomized trial being supported by the US NIH. I realize that "programmatic setting" is not a strictly defined term and exists on a spectrum where research is embedded within programs. But if the study paid for the digital adherence technology, staff monitoring treatment, or transport reimbursements, then it is hard to see how this is any more programmatic than the contexts of the 3HP efficacy trials, which had many sites in high-burden countries. If the authors want to make this distinction between their trial and previous trials, then I think further description is necessary about what the study supported and how this is more programmatic than previous trials.

2) Lines 91-92: I agree that data on acceptance and completion of 3HP in high-burden programmatic settings is sparse. However, I am not sure it is so sparse as to warrant omitting references to any examples or data from these settings. China has been using a twice-weekly version of 3HP programmatically (experience is reviewed in Cui et al. Management of latent tuberculosis infection in China: exploring solutions suitable for high-burden countries; other papers have been published reporting data from specific centers or studies). A program in Pakistan has been using 3HP and published on its experience (Yuen et al. Cost of delivering 12-dose isoniazid and rifapentine versus 6 months isoniazid for tuberculosis infection in a high-burden setting). The iAdhere trial whose US-specific results are mentioned in the preivous sentence incidentally also included a site in South Africa.

3) Could the authors provide a sentence or two more to describe the type of digital adherence technology used? I realize that this may be in the previous protocol paper, but since the message of this paper is that supportive systems of delivering 3HP can achieve high completion rates in a high-burden setting, I think it is important to understand exactly what those supportive systems are.

4) How was adverse event monitoring conducted? Verbal symptom screen? Was any routine laboratory monitoring performed? What evaluations were performed if patients reported signs/symptoms of a potential adverse event? I ask these questions because the secondary outcomes section reports the proportion of patients who had AE-related discontinuations, which is a very useful piece of information for programs. A description of AE monitoring would both help the reader assess the proportions being reported and also provide helpful information on how programs in high-burden settings can effectively monitor for AEs. Incidentally, if no routine laboratory monitoring was performed, it would be great if the authors could say this - one of the barriers frequently encountered to scaling up TB infection treatment in LMIC is the argument that the health system does not have the capacity for the type of LFT monitoring performed in high-income settings.

6) In the interest of making important information available to programs in high burden countries, it would be useful to know what the suspected 3HP-related adverse events were and their severity.

7) The discussion is rather abbreviated and does not delve much into discussing the supported self-administered mode of 3HP delivery, which I think is the most interesting aspect of this publication. Ultimately, the study reports an expected finding of high 3HP completion, which is consistent with the evidence from other trials, the substantial literature published by programs in low-burden settings, and the limited programmatic experience published to date from high-burden settings. To me, the value of this particular study is knowing how a program in a high-burden setting was able to achieve this high completion without DOT. Discussing this experience and comparing it to other experiences with digital adherence technology, which have been something of a mixed bag in terms of real-world effectiveness, would add great value to the paper.

Reviewer #3: The paper reports an interim analysis from a trial (3HP Options Trial) assessing the effect off three facilitated strategies of delivering 3HP regimen on treatment completion. The three study arms are facilitated DOT, facilitated SAT (including use of a digital adherence technology), and patient choice (with the assistance of a decision aid) between facilitated DOT and facilitated SAT. All participants receive automated dosing or clinic visit reminders weekly and are reimbursed transport costs for each clinic visit (11 visits for DOT & 2 for SAT).

The endpoint is treatment completion defined as accepting 3HP treatment and completing at least 11 of the 12 weekly doses within 16 weeks of enrolment. A Bayesian analysis was conducted to identify the posterior probability that at least one of the three arms will have treatment completion >80%. The analysis was based on participants randomised to 30 April 2021 with the target sample size expected to be completed in October 2022.

Introduction

1. The justification for this analysis was based on the urgent need for data in this in the context to aid in the global 3HP scaleup, particularly in Uganda. It is not clear how this aligns with Uganda policy on 3HP.

Methods

2. What is target sample size, expected to be completed in October 2022?

3. Is the trial design assessing for superiority or non-inferiority of study arms?

4. It is not clear what it meant by hybrid type 3 effectiveness-implementation design

5. How does this interim analysis relate to requests from external governance bodies such as a data safety monitoring board?

6. It is not clear how treatment completion is assessed in the three arms (doses taken at clinic visit, pill counts and /or DAT server data? ) - is the same method used across the three arms ?

7. Why is outcome of "initiating 3HP and completing at least 11 of the 12 weekly doses within 16 weeks of enrolment chosen"?

Results

8. How does the sample size in this interim analysis compare with the target sample size (expected to be completed in October 2022)?

Discussion

9. The authors concluded that "Taken together, these results demonstrate high levels of 3HP uptake and completion can be achieved in a programmatic setting when delivery strategies are designed to address known barriers to TPT completion." Given the intervention arms have varying degrees of support and therefore varying costs attached, how does this issue contribute to faster roll-out of 3HP in the region. Would be interesting for the authors to comment on whether the costing of the interventions would also influence the type of intervention to be rolled-out? Which of the three interventions will the authors be recommending to the Ministry of Health in Uganda?

10. The authors report on the recently completed trial in South Africa, Ethiopia and Mozambique which found high levels of treatment completion achieved in a programmatic context. They continue by saying that their study highlights the value of facilitated delivery deliveries - though in reality we do not know the effects of the different interventions as the interim analysis combined data across the three arms.

11. It would be useful for the authors to expand on their assertion that this ongoing analysis helped inform time critical public health questions. Are the authors recommending this type of analysis for similar scenarios?

Reviewer #4: This manuscript details an interim analysis of the ongoing 3HP Options Trial in Uganda, a randomized trial of DOT vs. SAT vs. SAT+DAT that is evaluating acceptance and completion rates across these three treatment strategies for TPT in PLHIV. Considering the need for more evidence for acceptance and adherence of these optimized strategies in the context of routine HIV care in sub-Saharan Africa, this manuscript will directly and substantially support the WHO's recommendation for using 3HP as an option for TPT in this setting.

The authors describe an inference analysis, estimating that at least one optimized treatment strategy would lead to >80% acceptance and completion of 3HP. Following their analysis, the authors demonstrated that all three strategies had a very high probability of exceeding 80% acceptance and treatment completion, effectively supporting that all three optimized strategies are highly effective in a sub-Saharan Africa context in Uganda.

The findings of this analysis are in context of previous literature on the topic, and the data analysis clearly supports the findings presented.

This manuscript details an interim analysis of an ongoing randomized trial and details of trial design have been previously published and are accessible via PubMed.

The overall study conforms to CONSORT guidelines for a randomized trial, and the methodology for the analysis to be reproduced.

Overall, the manuscript is well written, is accessible to non-specialists, and the findings will add to the body of evidence supporting high acceptability and completion rates for 3HP for TPT, using both DOT and SAT approaches, in the context of routine HIV care in sub-Saharan Africa.

Line-by-line minor comments, questions:

Line 90 - consider emphasizing that the Belknap study demonstrated that SAT was noninferior to DOT, but only specifically in the United States component of this study (further supports the authors' argument that evidence on 3HP acceptability and completion rates from studies conducted outside the United States, especially in SSA, is needed.

114 - is the digital adherence technology (DAT) text based? Consider adding explanation on what the participant was required to do with DAT. IVR is clearly explained in the manuscript.

129 - per the primary outcome: "the proportion of randomized participants who accept 129 3HP treatment and complete at least 11 of the 12 weekly doses within 16 weeks of enrollment." Did any participants who reached this outcome have a treatment interruption of 4 weeks before resuming weekly dosing and completing 3HP? I ask this as professional opinion can vary on the acceptable maximum treatment interruption allowed before a patient must restart 3HP (in my experience, between 1 and 4 weeks). Consider including the range of treatment interruption (in days) that was observed by this analysis for individuals who did successfully complete 3HP.

150 (Figure 1) - one 'did not meet inclusion criteria' in figure 1 states: "resistance to isoniazid (INH) or rifapentine (RPT) (n=2)". How was this determined/known? Were these individuals previously treated for active TB disease and now qualified for TPT? Seems that would not be the case as another 'did not meet inclusion criteria' is "prior treatment for TB/preventive TB". Please clarify.

179 - considering describing most common adverse event(s) that led to 1.7% of participants discontinuing treatment.

182 - unless it represents an increased risk for identifying the participant, consider including the name of the medication with a known 3HP interaction.

The Discussion section does not include limitations. I encourage you to discuss some possible limitations of your analysis. One plausible limitation is that this is an interim analysis of 3HP uptake for an ongoing study in Kampala, Uganda, and the acceptability and treatment completion rates observed in this setting may not reflect the probability of acceptance and completion of 3HP in other countries and settings in sub-Saharan Africa.

Overall, a well written manuscript. My recommendation is 'accept with minor revision'.

Clay Roscoe, MD MSc

HIV Services, Family Medicine Residency of Idaho, Boise, Idaho, USA

CMO, Sedia Biosciences, Beaverton, OR, USA

Reviewer #5: The authors present an interim analysis of limited data from the pragmatic randomized controlled trial, 3HP Options Trial, of the acceptance and completion (combined as a single outcome) of 3 months of weekly isoniazid and rifapentine (3HP) as TB preventive therapy (TBPT) in people living with HIV (PLHIV). The 3HP Options Trial aims to compare the acceptance, completion and costs (among other outcomes) of 3 different 3HP delivery strategies. The trial is still enrolling and the outcome data from all three arms were combined and included as an aggregate for this analysis. There is no comparator group.

TBPT can prevent TB disease in PLHIV and practical alternatives to 6 months of daily isoniazid (which is standard of care in many regions) make an important contribution to public health. 3HP has been shown to be as effective as isoniazid for this purpose and is recommended by the WHO. As the authors note, uptake in previous clinical trials has varied between 38-50% and 90%. In this analysis, the authors report high acceptance and completion of 3HP as TBTP (92.9%), and calculate that this (i.e. acceptance and completion) would exceed 80% if one of the three treatment strategies in the trial were used in this setting. These results did not vary by sex, age or time on antiretroviral therapy.

The primary outcome/s of the 3HP Options Trial will hopefully indicate a best practice for dispensing 3HP to PLHIV in Uganda. Other elements of the study design may provide a template for stakeholder and community engagement and support patient-centred care. The aggregation of the data in these analyses limits the novelty and usefulness of the results. In addition, as presented, the description of the settings and methods do not support the conclusion that the results are generalizable to a programmatic setting.

The manuscript is very well-written however, the impact is overstated. It may be better suited to an alternative publication. Given the remit that 'papers published in PLOS Medicine should be of the highest technical quality and be seen as significant advances within their own discipline and beyond' I do not think this interim analysis is suitable for publication in this journal.

Major comments

While the 3HP Options Trial may be implemented in a routine clinical setting, the trial study procedures are not routine and vary from intensive observed monitoring (with re-imbursement for visits) to digital adherence monitoring and automated dosing and clinic reminders. The implication that the results have been achieved in a programmatic context (line 198) is that they are generalizable to similar routine clinical settings in Uganda and elsewhere in sub-Saharan Africa. Such practices described above are not routine in most programs which are often under-resourced.

The authors reference the 3HP Options Trial protocol but do not describe the setting, including physical, technological and human resources. Did clinic staff receive incentives for participating in the trial management? What was the source of funds for re-imbursement? At what level was the political and management support provided? Related to the lack of detail in the methodology, streamlined clinic visits and other patient-centred (line 202) and facilitated delivery strategies (line 186) are not described but are alluded to in the discussion. In addition, one of the strengths of the study design is noted to be the engagement of relevant stakeholders (210), but this does not appear elsewhere in the manuscript (methods or results).

Minor comments

Is the trial registered?

Study design: The power calculations have been based on the parent study which aims to enrol 1656 adults. Approximately 30% of the target have been enrolled. Is this sufficient for the interim analysis to be meaningful?

As noted above, the background planning and the integration of the study procedures into the routine setting are not well described. This is necessary if the conclusion drawn is that the systems work in a program setting.

Any attachments provided with reviews can be seen via the following link:

[LINK]

Attachment

Submitted filename: Review notes.docx

Click here for additional data file.^{(15.6KB, docx)}

PLoS Med. 2021 Dec 16;18(12):e1003875. doi: 10.1371/journal.pmed.1003875.r003

Author response to Decision Letter 1

28 Oct 2021

Attachment

Submitted filename: 3HP Options Trial_Interim Analysis_Review response_final.docx

Click here for additional data file.^{(145.4KB, docx)}

PLoS Med. doi: 10.1371/journal.pmed.1003875.r004

Decision Letter 2

Callam Davidson

17 Nov 2021

Dear Dr. Cattamanchi,

Thank you very much for re-submitting your manuscript "Completion of Isoniazid-Rifapentine (3HP) for tuberculosis (TB) prevention among people living with HIV (PLHIV): interim analysis of a hybrid type 3 effectiveness-implementation randomized trial" (PMEDICINE-D-21-03667R2) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by five reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

[LINK]

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. If you haven't already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript.

Please note, when your manuscript is accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosmedicine@plos.org.

If you have any questions in the meantime, please contact me or the journal staff on plosmedicine@plos.org.

We look forward to receiving the revised manuscript by Nov 24 2021 11:59PM.

Sincerely,

Callam Davidson,

Associate Editor

PLOS Medicine

plosmedicine.org

------------------------------------------------------------

Requests from Editors:

Please remove the abbreviations "TB" and "PLHIV" from the title.

Please include the baseline summary data (from lines 251-253) in your abstract.

Line 119: Please state the number of patients discontinued (8) as well as the percentage.

Please define AST and ALT in Figure 1.

Thank you for including a STARI checklist. Please adapt the checklist to use sections and paragraph numbers rather than page numbers (which will likely change during the revision process). Column headers can be updated to reflect this change (from 'page number' to 'Section name and paragraph number', or similar).

To help us extend the reach of your research, please provide any Twitter handle(s) that would be appropriate to tag, including your own, your co-authors, your institution, funder, or lab.

Comments from Reviewers:

Reviewer #1: We thank the authors for acknowledging our prior concerns. The main reservation remains that this is an interim analysis with arm-specific details unable to be further provided to maintain the integrity of the ongoing trial. That said, the primary objective (i.e. a greater than 99% probability that treatment acceptance and completion would exceed 80%, under at least one of the three strategies) appear highly likely to have been attained, and the release of these interim results (as opposed to late 2023 for the full results) would appear to help guide 3HP treatment promptly. Considering this, we have in principle no objection to the release of these results if judged significant enough by the editors, particularly if the inability to reveal arm-stratified analysis is further emphasized as a limitation.

Reviewer #2: Thank you to the authors for the revision. The paper is substantially more balanced in the way it contextualizes its significance, and it is more informative for programs considering how to deliver 3HP in high-burden settings. I agree with the other reviewers who have questioned the importance of an interim results publication that neither answers the question of how best 3HP can be delivered nor discusses the implementation experience with these methods (presumably saving both for what will be the "main" trial publication). However, I think that on the balance, the information that is now presented about the use of 99DOTS, adverse event monitoring under programmatic conditions, and the use of transport reimbursements and other patient support strategies, in the context of overall high treatment completion, gives sufficient value to warrant more prompt dissemination.

The one comment I have is the added citation of the RE-AIM framework. I am sure that the larger study was indeed designed using the RE-AIM framework, but it is difficult to see how this interim report maps to it. It is not clear from the description of the trial that 3HP is the intervention and DOT/99DOTS are the implementation strategies, so it is hard to intuitively see treatment completion as a fidelity measure since it is often treated as a proxy effectiveness measure. In addition, it is confusing to cite use of the RE-AIM framework when only two of the components are addressed as a composite outcome, and the other three are not addressed at all (adoption and maintenance are not even mentioned among the outcomes referenced in the protocol). I suggest clarifying in the study design section that 3HP is the evidence-based intervention and that DOT vs supported SAT are the implementation strategies being assessed. And I suggest either briefly summarizing the main outcomes corresponding to the RE-AIM components or at the very least being explicit that this interim analysis addresses only a combined reach+implementation fidelity outcome, while the other RE-AIM components will be more fully assessed at the end of the trial.

Reviewer #3: Thank you for your detailed response to comments. My concerns have been addressed.

Reviewer #4: I very much agree with Reviewer #5's comment that this interim research, overall, may not meet full PLOS Medicine criteria for publication, which includes the language that publications "be seen as significant advances within their own discipline and beyond". As an interim analysis of 3HP TPT acceptance and completion, based on aggregated data across the study arms being evaluated, this manuscript may not fully fit PLOS Medicine criteria for publication. Though this interim analysis does not address the question of how best 3HP can be delivered in a high-burden setting (the authors do state the final research will address this), it does, importantly, provide one of the first examples of 3HP being delivered in a programmatic setting in a high-burden country, demonstrating positive acceptance and fidelity of 3HP, in general. For the latter findings, I recommend this manuscript be accepted for publication, but respectfully defer to the Editor's final decision on if this manuscript represents a significant advance in the field of TPT and meets journal criteria for publication.

Reviewer #5: Much more detail and clarity has been provided and the manuscript improved. The tone has been moderated and the data presented more appropriately (to my mind); my comments have been addressed. The manuscript is sound and well-written.

I am still not certain that the impact is sufficient for publication in PLOS MEDICINE, but the editors are better placed in this regard.

Any attachments provided with reviews can be seen via the following link:

[LINK]

PLoS Med. 2021 Dec 16;18(12):e1003875. doi: 10.1371/journal.pmed.1003875.r005

Author response to Decision Letter 2

23 Nov 2021

Attachment

Submitted filename: 3HP Options Trial_Interim Analysis_2nd Review response.docx

Click here for additional data file.^{(29.9KB, docx)}

PLoS Med. doi: 10.1371/journal.pmed.1003875.r006

Decision Letter 3

Callam Davidson

25 Nov 2021

Dear Dr Cattamanchi,

On behalf of my colleagues and the Academic Editor, Dr Claudia Denkinger, I am pleased to inform you that we have agreed to publish your manuscript "Completion of Isoniazid-Rifapentine (3HP) for tuberculosis prevention among people living with HIV: interim analysis of a hybrid type 3 effectiveness-implementation randomized trial" (PMEDICINE-D-21-03667R3) in PLOS Medicine.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Once you have received these formatting requests, please note that your manuscript will not be scheduled for publication until you have made the required changes.

When making the required changes, please also remove the 'Funding' and 'Conflicts of interest' sections from your title page (both will be published as metadata based on your response to the relevant submission form question).

In the meantime, please log into Editorial Manager at http://www.editorialmanager.com/pmedicine/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production process.

PRESS

We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with medicinepress@plos.org. If you have not yet opted out of the early version process, we ask that you notify us immediately of any press plans so that we may do so on your behalf.

We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit http://www.plos.org/about/media-inquiries/embargo-policy/.

Thank you again for submitting to PLOS Medicine. We look forward to publishing your paper.

Sincerely,

Callam Davidson

Associate Editor

PLOS Medicine

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 CONSORT Checklist. CONSORT 2010 checklist of information to include when reporting a randomized trial.

CONSORT, Consolidated Standards of Reporting Trials.

(DOC)

Click here for additional data file.^{(94.5KB, doc)}

S1 StaRI Checklist. StaRI: The StaRI checklist for completion.

StaRI, Standards for Reporting Implementation Studies.

(DOCX)

Click here for additional data file.^{(43.6KB, docx)}

S1 Data. Raw deidentified data used to conduct this analysis.

(CSV)

Click here for additional data file.^{(65.4KB, csv)}

S1 Statistical Analysis Plan. 3HP Options Trial: Interim analysis statistical analysis plan.

(DOCX)

Click here for additional data file.^{(96.3KB, docx)}

S1 Trial Protocol. Options for delivering isoniazid–rifapentine (3HP) for TB prevention (3HP options implementation trial).

TB, tuberculosis.

(DOCX)

Click here for additional data file.^{(263.7KB, docx)}

S1 Text. Side effects and symptom-based TB screening checklist.

TB, tuberculosis.

(DOCX)

Click here for additional data file.^{(16KB, docx)}

S2 Text. Serious AEs summary.

AE, adverse event.

(DOCX)

Click here for additional data file.^{(22KB, docx)}

Attachment

Submitted filename: Review notes.docx

Click here for additional data file.^{(15.6KB, docx)}

Attachment

Submitted filename: 3HP Options Trial_Interim Analysis_Review response_final.docx

Click here for additional data file.^{(145.4KB, docx)}

Attachment

Submitted filename: 3HP Options Trial_Interim Analysis_2nd Review response.docx

Click here for additional data file.^{(29.9KB, docx)}

Data Availability Statement

All relevant data are within the manuscript and its Supporting information files.

[pmed.1003875.ref001] 1.World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization; 2020.

[pmed.1003875.ref002] 2.Group TAS, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015;373(9):808–22. doi: 10.1056/NEJMoa1507198 [DOI] [PubMed] [Google Scholar]

[pmed.1003875.ref003] 3.Badje A, Moh R, Gabillard D, Guehi C, Kabran M, Ntakpe JB, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–e9. doi: 10.1016/S2214-109X(17)30372-8 [DOI] [PubMed] [Google Scholar]

[pmed.1003875.ref004] 4.Melgar M, Nichols C, Cavanaugh JS, Kirking HL, Surie D, Date A, et al. Tuberculosis Preventive Treatment Scale-Up Among Antiretroviral Therapy Patients—16 Countries Supported by the U.S. President’s Emergency Plan for AIDS Relief, 2017–2019. MMWR Morb Mortal Wkly Rep. 2020;69(12):329–34. doi: 10.15585/mmwr.mm6912a3 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref005] 5.Roscoe C, Lockhart C, de Klerk M, Baughman A, Agolory S, Gawanab M, et al. Evaluation of the uptake of tuberculosis preventative therapy for people living with HIV in Namibia: a multiple methods analysis. BMC Public Health. 2020;20(1):1838. doi: 10.1186/s12889-020-09902-z [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref006] 6.Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269–78. doi: 10.1016/S1473-3099(16)30216-X [DOI] [PubMed] [Google Scholar]

[pmed.1003875.ref007] 7.Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66. doi: 10.1056/NEJMoa1104875 [DOI] [PubMed] [Google Scholar]

[pmed.1003875.ref008] 8.Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11–20. doi: 10.1056/NEJMoa1005136 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref009] 9.Moro RN, Borisov AS, Saukkonen J, Khan A, Sterling TR, Villarino ME, et al. Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada. Clin Infect Dis. 2016;62(11):1390–400. doi: 10.1093/cid/ciw126 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref010] 10.Belknap R, Holland D, Feng PJ, Millet JP, Cayla JA, Martinson NA, et al. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. Ann Intern Med. 2017;167(10):689–97. doi: 10.7326/M17-1150 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref011] 11.Yuen CM, Majidulla A, Jaswal M, Safdar N, Malik AA, Khan AJ, et al. Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting. Clin Infect Dis. 2021;73(5):e1135–e41. doi: 10.1093/cid/ciaa1835 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref012] 12.Cui X, Gao L, Cao B. Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries. Int J Infect Dis. 2020;92S:S37–40. doi: 10.1016/j.ijid.2020.02.034 [DOI] [PubMed] [Google Scholar]

[pmed.1003875.ref013] 13.Brown CH, Curran G, Palinkas LA, Aarons GA, Wells KB, Jones L, et al. An Overview of Research and Evaluation Designs for Dissemination and Implementation. Annu Rev Public Health. 2017;38:1–22. doi: 10.1146/annurev-publhealth-031816-044215 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref014] 14.Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, et al. Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implement Sci. 2020;15(1):65. doi: 10.1186/s13012-020-01025-8 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref015] 15.Kadota JL, Katamba A, Musinguzi A, Welishe F, Nabunje J, Ssemata JL, et al. Willingness to accept reimbursement for visits to an HIV clinic for tuberculosis preventive therapy. Int J Tuberc Lung Dis. 2020;24(7):729–31. doi: 10.5588/ijtld.20.0010 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref016] 16.Lim RK, Semitala FC, Atuhumuza E, Sabiti L, Namakula-Katende J, Muyindike WR, et al. Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda. PLoS ONE. 2021;16(2):e0246113. doi: 10.1371/journal.pone.0246113 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref017] 17.Semitala FC, Musinguzi A, Ssemata JL, Welishe F, Nabunje J, Kadota JL, et al. Acceptance and completion of rifapentine based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda—patient and health worker perspectives. Implementation Science. IDAA Commun. 2021;2. doi: 10.1186/s43058-021-00173-2 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref018] 18.Subbaraman R, de Mondesert L, Musiimenta A, Pai M, Mayer KH, Thomas BE, et al. Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities. BMJ Glob Health. 2018;3(5):e001018. doi: 10.1136/bmjgh-2018-001018 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref019] 19.Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322–7. doi: 10.2105/ajph.89.9.1322 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref020] 20.Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, DB R. Bayesian data analysis. Boca Raton: CRC Press; 2014. [Google Scholar]

[pmed.1003875.ref021] 21.Global Multidimensional Poverty index 2020 –Charting Pathways out of Multidimensional Poverty: Achieving the SDGs. UNDP and OPHI. 2020.

[pmed.1003875.ref022] 22.Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JA, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69(4):1079–85. doi: 10.1093/jac/dkt483 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref023] 23.Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, et al. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. Clin Infect Dis. 2015;61(8):1322–7. doi: 10.1093/cid/civ464 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref024] 24.Sandul AL, Nwana N, Holcombe JM, Lobato MN, Marks S, Webb R, et al. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection. Clin Infect Dis. 2017;65(7):1085–93. doi: 10.1093/cid/cix505 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref025] 25.Walker RE, Bass S, Srinivas P, Miranda C, Johnson L, Pallotta AM. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection. Ann Pharmacother. 2020;54(5):457–63. doi: 10.1177/1060028019888855 [DOI] [PubMed] [Google Scholar]

[pmed.1003875.ref026] 26.Sun HY, Huang YW, Huang WC, Chang LY, Chan PC, Chuang YC, et al. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan. Tuberculosis (Edinb). 2018;111:121–6. doi: 10.1016/j.tube.2018.05.013 [DOI] [PubMed] [Google Scholar]

[pmed.1003875.ref027] 27.Haas MK, Aiona K, Erlandson KM, Belknap RW. Higher Completion Rates with Self-administered Once-weekly Isoniazid-Rifapentine versus Daily Rifampin in Adults with Latent Tuberculosis. Clin Infect Dis. 2020. [DOI] [PubMed] [Google Scholar]

[pmed.1003875.ref028] 28.Churchyard G, Cardenas V, Chihota V, Mngadi K, Sebe M, Brumskine W, et al. Annual Tuberculosis Preventive Therapy for Persons With HIV Infection: A Randomized Trial. Ann Intern Med. 2021. doi: 10.7326/M20-7577 [DOI] [PubMed] [Google Scholar]

[pmed.1003875.ref029] 29.Consolidated Guidelines for the Prevention and Treatment of HIV and AIDS in Uganda. In: Ministry of Health, Kampala, Uganda. 2020.

[pmed.1003875.ref030] 30.Yuen CM, Millones AK, Galea JT, Puma D, Jimenez J, Lecca L, et al. Toward patient-centered tuberculosis preventive treatment: preferences for regimens and formulations in Lima, Peru. BMC Public Health. 2021;21(1):121. doi: 10.1186/s12889-020-10098-5 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref031] 31.Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, et al. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS. 2010;24(Suppl 5):S57–65. doi: 10.1097/01.aids.0000391023.03037.1f [DOI] [PubMed] [Google Scholar]

[pmed.1003875.ref032] 32.Jacobson KB, Niccolai L, Mtungwa N, Moll AP, Shenoi SV. "It’s about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa. AIDS Care. 2017;29(7):936–42. doi: 10.1080/09540121.2017.1283390 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref033] 33.Rowe KA, Makhubele B, Hargreaves JR, Porter JD, Hausler HP, Pronyk PM. Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings? Int J Tuberc Lung Dis. 2005;9(3):263–9. [PubMed] [Google Scholar]

[pmed.1003875.ref034] 34.Mindachew M, Deribew A, Memiah P, Biadgilign S. Perceived barriers to the implementation of Isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study. Pan Afr Med J. 2014;17:26. doi: 10.11604/pamj.2014.17.26.2641 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref035] 35.Kim HY, Hanrahan CF, Dowdy DW, Martinson NA, Golub JE, Bridges JFP. Priorities among HIV-positive individuals for tuberculosis preventive therapies. Int J Tuberc Lung Dis. 2020;24(4):396–402. doi: 10.5588/ijtld.18.0740 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref036] 36.Cowan J, Greenberg Cowan J, Barnhart S, Demamu S, Fiseha D, Graham W, et al. A qualitative assessment of challenges to tuberculosis management and prevention in Northern Ethiopia. Int J Tuberc Lung Dis. 2013;17(8):1071–5. doi: 10.5588/ijtld.12.0240 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref037] 37.Gust DA, Mosimaneotsile B, Mathebula U, Chingapane B, Gaul Z, Pals SL, et al. Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana. PLoS ONE. 2011;6(4):e18435. doi: 10.1371/journal.pone.0018435 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pmed.1003875.ref038] 38.Makanjuola T, Taddese HB, Booth A. Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: a systematic review of qualitative data. PLoS ONE. 2014;9(2):e87166. doi: 10.1371/journal.pone.0087166 [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Completion of isoniazid–rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness–implementation randomized trial

Fred C Semitala

Jillian L Kadota

Allan Musinguzi

Juliet Nabunje

Fred Welishe

Anne Nakitende

Lydia Akello

Opira Bishop

Devika Patel

Amanda Sammann

Payam Nahid

Robert Belknap

Moses R Kamya

Margaret A Handley

Patrick P J Phillips

Anne Katahoire

Christopher A Berger

Noah Kiwanuka

Achilles Katamba

David W Dowdy

Adithya Cattamanchi

Roles

Abstract

Background

Methods and findings

Conclusions

Trial registration

Author summary

Why was this study done?

What did the researchers do and find?

What do these findings mean?

Introduction

Methods

Study design and participants

Fig 1. CONSORT flow diagram.

Randomization and interventions

Assessments and data collection

Trial outcomes

Statistical analysis

Results

Table 1. Baseline demographic and clinical characteristics.

Primary outcome

Fig 2. 3HP acceptance and completion, by subgroup.

Secondary outcomes

Discussion

Supporting information

Acknowledgments

Abbreviations

Data Availability

Funding Statement

References

Decision Letter 0

Callam Davidson

Roles

Decision Letter 1

Callam Davidson

Roles

Author response to Decision Letter 1

Decision Letter 2

Callam Davidson

Roles

Author response to Decision Letter 2

Decision Letter 3

Callam Davidson

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases